Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON23071
NL-OMON23071
Recruiting
Not Applicable

Validation and comparison of risk prediction scores for venous thromboembolism in ambulatory cancer patients.

Amsterdam UMC0 sites2,000 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCancer-associated venous thromboembolism

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer-associated venous thromboembolism
Sponsor
Amsterdam UMC
Enrollment
2000
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • •Adult patients (age \>18 years)
  • •\-Ambulatory setting
  • •\-Histologically or cytologically confirmed cancer
  • •\-Chemotherapy indicated within 3 months

Exclusion Criteria

  • •\-Desmoid tumors
  • •\-Pre\-stages of cancer

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
To Validate the Risk Scoring System that is developed by Madras Medical Mission, to predict whether the contrast used during the procedure of angioplasty would result in any alteration of kidney functio
CTRI/2014/10/005080The Madras Medical Mission Hospital5,000
Completed
Not Applicable
Practical risk stratification score for prediction of contrast-induced nephropathy after primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction: development and internal validatioContrast&#45induced nephropathy was defined as the deterioration of renal function following the administration of contrast agents and unlikely to be explained by other possible causes. Patients with anprediction score&#44contrast&#45induced nephropathy&#44STEMI
TCTR20190705001/A217
Completed
Not Applicable
Risk model to predict adverse outcomes after primary percutaneous coronary intervention (PCI)
ISRCTN83474650Clinical Center of Serbia (Serbia)1,750
Completed
Not Applicable
Development and validation of a risk scoring system to predict surgical-site infection after soft-tissue sarcoma resectioSoft tissue sarcoma
JPRN-jRCT1040220108Miwa Shinji500
Not yet recruiting
Not Applicable
A risk-predictive score for developing Non-Alcoholic Fatty Liver Disease (NAFLD) using biochemical markersHealth Condition 1: K758- Other specified inflammatory liverdiseases
CTRI/2022/12/048328PG Grants, Kasturba Medical College